Corey Cutler, MD
Enriched profileDirector, Adult Stem Cell Transplantation Program; Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
Corey Cutler is Director, Adult Stem Cell Transplantation Program; Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 834 publications with 42,105 citations (h-index 106); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Corey Cutler, MD, is Director, Adult Stem Cell Transplantation Program at Dana-Farber Cancer Institute, Boston, MA. The public record shows 834 publications with 42,105 citations (h-index 106), centered on Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 24 companies, 3 NIH-funded awards (2013–2025).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Hematopoietic Stem Cell Transplantation
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 350.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Sponsor: Dana-Farber Cancer Institute
- Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 27 Aug 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SANOFI-AVENTIS U.S. LLCProgram year202512 payments$29,848openpaymentsdata.cms.gov ↗
- SANOFI US SERVICES INC.Program year20257 payments$21,262openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20258 payments$17,841openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
62.1%Kinase inhibitor36.4%Jakafi89%Iclusig12%Part D<11 patientsSelective immunosuppressants18.6%Rezurock100%Part D≥16 patientsAntiparasitic
10.6%Antimalarial10.6%Atovaquone100%Part D≥13 patientsDermatology
8.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor8.3%Acyclovir100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2013–2025 per NIH RePORTER. The latest:
- Mechanisms and Therapy of Chronic Graft-vs.-Host Disease
Dana-Farber Cancer Inst
FY2025$2,563,941P01HL158505
Congress activity
Updated 27 Aug 2026
69 congress contributions (2009–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Impact of static and dynamic risk assessment in HMA-treated MDS patients undergoing stem cell transplantation.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.
Journal of clinical oncology
Clinical Trial2026 - Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study.
Blood advances
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/corey-cutler-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - X / Twitter
x.com/DrCCutler
Mentions by others
where others cite or feature them- Other
aamds.org/bio/corey-cutler-md-mph-frcpc
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗ - Other
aamds.org/podcast/new-marrow-sct-bmt-and-gvhd-dr-corey-cutler-medical-director-stem-cell-transplantation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗ - LinkedIn
linkedin.com/posts/dana-farber-cancer-institute_in-late-februarycorey-cutler-md-mph-activity-7167956009880129537-Df8C
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- MD
McGill University Faculty of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - MPH
Harvard School of Public Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - FRCPC
Fellow of the Royal College of Physicians of Canada
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newswire.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →higherlogicdownload.s3.amazonaws.com ↗
- Editorial board member
Biology of Blood and Marrow Transplantation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →newswire.com ↗
Awards & honors
honors on the public record- Top Doctor Award2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Department of Medicine
Brigham and Women's Hospital
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →providers.dana-farberbrigham.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute